Clinical Trial Update: P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating AMG 531 in thrombocytopenic Japanese patients with idiopathic thrombocytopenic purpura has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura

Drugs mentioned

• AMG 531 (AMG531)

Snippet

Sponsor: Amgen | Conditions: Idiopathic Thrombocytopenic Purpura | Phase 3 | Status: COMPLETED | Results posted: 2010-12-10